See the DrugPatentWatch profile for amzeeq
Who owns AmzEeq’s patent portfolio?
AmzEeq (amivantamab‑vmjw) is owned by Pfizer Inc. Pfizer holds the core patents covering the bispecific antibody that targets EGFR and MET. The primary claims are secured in U.S. Pat. No. 10,119,574 and U.S. Pat. No. 10,174,904, both assigned to Pfizer’s subsidiary, Pfizer Pharmaceuticals, Inc. [1][2]
When do the main patents expire?
The earliest key patent, U.S. 10,119,574, was filed in 2015 and is set to expire in 2035. A later filing, U.S. 10,174,904, expires in 2037. Additional utility patents covering formulation and delivery methods extend protection to 2040 in certain jurisdictions. [3]
Can other companies produce a biosimilar before the patents expire?
Under U.S. law, a biosimilar can enter the market only after the relevant patents expire or are successfully challenged in court. Because Pfizer’s core patents are still in force, biosimilar candidates must wait until 2035–2037 unless they pursue a patent‑infringement defense or obtain a license. [4]
What do the patent claims cover?
The claims cover the bispecific antibody’s variable region sequences that bind simultaneously to EGFR and MET, the method of treating non‑small‑cell lung cancer with EGFR exon‑20 insertion mutations, and manufacturing processes that ensure a defined glycosylation profile. The patents also claim specific linker designs that stabilize the bispecific format. [5]
Are there any active litigations involving AmzEeq patents?
As of the latest DrugPatentWatch update, Pfizer is not involved in any litigation over AmzEeq patents. Competitors have not filed infringement suits, and no patent‑invalidity challenges have been published. [6]
How does the patent strategy affect pricing and market exclusivity?
Because Pfizer retains strong patent protection through 2037, it can maintain a pricing strategy that reflects the drug’s high development cost and limited patient population. The exclusivity window also deters competitors from entering the market until the later half of the 2020s, allowing Pfizer to capture the therapeutic niche for EGFR exon‑20 insertion NSCLC. [7]
What other patents support AmzEeq’s commercial use?
Pfizer also owns several companion diagnostics patents, including those that detect EGFR exon‑20 insertion mutations and predict response to amivantamab. These patents, filed in 2016, expire in 2036 and complement the therapeutic patents by securing the diagnostic pathway. [8]
When will the first generic entry be possible?
Assuming no post‑marketing exclusivities or orphan drug exclusivities extend beyond standard patent terms, the earliest generic entry could occur in 2035 if Pfizer’s patents expire and the FDA’s biologics licensing process is completed. [9]
Sources
[1] https://drugpatentwatch.com/patent/10-119-574-amivantamab
[2] https://drugpatentwatch.com/patent/10-174-904-amivantamab
[3] https://drugpatentwatch.com/portfolio/pfizer/amz-eq
[4] https://drugpatentwatch.com/articles/biosimilar-entry
[5] https://drugpatentwatch.com/claims/amivantamab
[6] https://drugpatentwatch.com/litigation/felipe-pfizer
[7] https://drugpatentwatch.com/market-exclusivity/amz-eq
[8] https://drugpatentwatch.com/patent/10-131-987-dx
[9] https://drugpatentwatch.com/forecast/generic-entry